Lilly shares safety, tolerability data on its next-gen obesity drug statnews.com
Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications investor.lilly.com
Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits Reuters
ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes Fierce Biotech
A new wave of weight-loss therapies aims to be better than today’s GLP-1s MarketWatch